Maze Therapeutics SVP Sells 5,000 Shares Amid Historic First Year for the Company's Stock
Maze Therapeutics' Senior Vice President of Finance sold shares towards the end of January 2026, all while the company's stock had one of the best first-year performances of a biopharmaceutical company.